Sun Pharma has signed an agreement to buy a manufacturing facility in Bryan, Ohio from Valeant Pharmaceuticals International. Terms of the transaction were not disclosed.
Dilip Shanghvi, Sun Pharma’s Chairman and Managing Director, said, "This acquisition will help us accelerate filings for the US generic market and address opportunities in liquids and semisolids like creams and ointments, where we have interesting products in development. This will complement our US strategy as an integrated company, with filings from an Indian site, our subsidiary Caraco Pharma Labs (Amex :CPD), with capability across various dosage forms and marketing those dosage forms through Caraco in the US.”
In the Indian market, Sun Pharma is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology and orthopedics.